Journal article

Enhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells.

Sai Priya Anand, Shilei Ding, William D Tolbert, Jérémie Prévost, Jonathan Richard, Hwi Min Gil, Gabrielle Gendron-Lepage, Wing-Fai Cheung, Haifeng Wang, Rebecca Pastora, Hirak Saxena, Warren Wakarchuk, Halima Medjahed, Bruce D Wines, Mark Hogarth, George M Shaw, Malcom A Martin, Dennis R Burton, Lars Hangartner, David T Evans Show all

J Virol | Published : 2021


The activity of broadly neutralizing antibodies (bNAbs) targeting HIV-1 depends on pleiotropic functions, including viral neutralization and the elimination of HIV-1-infected cells. Several in vivo studies have suggested that passive administration of bNAbs represents a valuable strategy for the prevention or treatment of HIV-1. In addition, different strategies are currently being tested to scale up the production of bNAbs to obtain the large quantities of antibodies required for clinical trials. Production of antibodies in plants permits low-cost and large-scale production of valuable therapeutics; furthermore, pertinent to this work, it also includes an advanced glycoengineering platform...

View full abstract

University of Melbourne Researchers


Awarded by NIGMS NIH HHS

Awarded by NIAID NIH HHS

Awarded by HHS | National Institutes of Health (NIH)

Awarded by Gouvernement du Canada | National Research Council Canada (NRC)

Awarded by Gouvernement du Canada | Canadian Institutes of Health Research (CIHR)